<document>

<filing_date>
2018-08-21
</filing_date>

<publication_date>
2020-11-26
</publication_date>

<priority_date>
2017-08-21
</priority_date>

<ipc_classes>
C07K14/47,C12N15/62
</ipc_classes>

<assignee>
UNIVERSITY OF KANSAS
</assignee>

<inventors>
Wisdom, Emily Caitlyn
Tamerler-Behar, Candan
Boone, Kyle
</inventors>

<docdb_family_id>
65439244
</docdb_family_id>

<title>
CHIMERIC PEPTIDE FOR A BIOMIMETIC IMPLANT INTERFACE
</title>

<abstract>
Provided in this disclosure are chimeric peptides that include a spacer domain, the spacer domain itself, substrates (e.g., implants) coated with the chimeric peptides, and methods for making and using the coated substrates.
</abstract>

<claims>
1. A chimeric peptide comprising an inorganic binding domain having an amino acid sequence selected to bind to an inorganic surface, an antimicrobial domain having an amino acid sequence selected to exhibit antimicrobial activity, and a spacer domain between the inorganic binding domain and the antimicrobial domain, the spacer domain having an amino acid sequence engineered to retain the antimicrobial activity of the antimicrobial domain.
2. (canceled)
3. (canceled)
4. (canceled)
5. (canceled)
6. (canceled)
7. (canceled)
8. The chimeric peptide of claim 1, wherein the spacer domain amino acid sequence is GSGGG (SEQ ID NO: 2).
9. The chimeric peptide of claim 1, wherein the antimicrobial domain amino acid sequence exhibits antimicrobial activity against bacteria associated with clinic implant infections.
10. The chimeric peptide of claim 9, wherein the bacteria comprise S. mutans, S. epidermidis, and combinations thereof.
11. (canceled)
12. (canceled)
13. The chimeric peptide of claim 1, wherein the inorganic binding domain amino acid sequence is that of a titanium binding peptide, and the antimicrobial domain amino acid sequence is that of an antimicrobial domain exhibiting antimicrobial activity against S. mutans, S. epidermidis, or combinations thereof.
14. The chimeric peptide of claim 13, wherein the inorganic binding domain amino acid sequence is RPRENRGRERGL (SEQ ID NO: 7) and the antimicrobial domain acid sequence is LKLLKKLLKLLKKL (SEQ ID NO: 8).
15. The chimeric peptide of claim 14, wherein the spacer domain amino acid sequence is GSGGG (SEQ ID NO: 2).
16. The chimeric peptide of claim 1, wherein the inorganic binding domain amino acid sequence is selected from the group consisting of: RPRENRGRERGL (SEQ ID NO: 7), GRAVRRSIRRRV (SEQ ID NO: 20), AIRGIRGIRGIR (SEQ ID NO: 21), CMLPHHGAC (SEQ ID NO: 36), RPRENRGRERF (SEQ ID NO: 40), and RPREQRGRER (SEQ ID NO: 41); the antimicrobial domain acid sequence is selected from the group consisting of: LKLLKKLLKLLKKL (SEQ ID NO: 8), ESYKRMF (SEQ ID NO: 14), ESYKHMF (SEQ ID NO: 15), ATLGVLWEGARGHT (SEQ ID NO: 18), KWKLWKKIEKWGQGIGAVLKWLTTWL (SEQ ID NO: 22), KRWWKWWRR (SEQ ID NO: 37), and KWKRWWWWR (SEQ ID NO: 39); and the spacer domain amino acid sequence is selected from the group consisting of: GGG (SEQ ID NO: 1), GSGGG (SEQ ID NO: 2); KGSVLSAD (SEQ ID NO: 23), WLMNYFWPL (SEQ ID NO: 42), YLMNYLLPY (SEQ ID NO: 43), PKSALQEL (SEQ ID NO: 44), IGVVISAV (SEQ ID NO: 45), KGSVYLLPY (SEQ ID NO: 46), and WLMNLSAD (SEQ ID NO: 47).
17. The chimeric peptide of claim 1, wherein the inorganic binding domain amino acid sequence is that of acrylic polymer binding peptide and/or a polyurethane binding peptide, and the antimicrobial domain amino acid sequence is that of an antimicrobial domain exhibiting antimicrobial activity against S. mutans, S. epidermidis, or combinations thereof.
18. The chimeric peptide of claim 17, wherein the inorganic binding domain amino acid sequence is selected from GRAVRRSIRRRV (SEQ ID NO: 20) and AIRGIRGIRGIR (SEQ ID NO: 21); the antimicrobial domain acid sequence is selected from LKLLKKLLKLLKKL (SEQ ID NO: 8) and KWKLWKKIEKWGQGIGAVLKWLTTWL (SEQ ID NO: 22); and the spacer domain amino acid sequence is selected from GGG (SEQ ID NO: 1), GSGGG (SEQ ID NO: 2), and KGSVLSAD (SEQ ID NO: 23).
19. The chimeric peptide of claim 1, wherein the inorganic binding domain amino acid sequence is that of calcium phosphate binding peptide, and the antimicrobial domain amino acid sequence is that of an antimicrobial domain exhibiting antimicrobial activity against S. mutans, S. epidermidis, or combinations thereof.
20. The chimeric peptide of claim 19, wherein the inorganic binding domain amino acid sequence is CMLPHHGAC (SEQ ID NO: 36) and the antimicrobial domain acid sequence is KRWWKWWRR (SEQ ID NO: 37).
21. The chimeric peptide of claim 20, wherein the spacer domain amino acid sequence is GGG (SEQ ID NO: 1).
22. The chimeric peptide of claim 1, wherein the inorganic binding domain amino acid sequence is that of zirconia binding peptide, and the antimicrobial domain amino acid sequence is that of an antimicrobial domain exhibiting antimicrobial activity against S. mutans, S. epidermidis, or combinations thereof.
23. The chimeric peptide of claim 22, wherein the inorganic binding domain amino acid sequence is selected from RPRENRGRERF (SEQ ID NO: 40) and RPREQRGRER (SEQ ID NO: 41); the antimicrobial domain acid sequence is selected from LKLLKKLLKLLKKL (SEQ ID NO: 8) and KWKRWWWWR (SEQ ID NO: 39); and the spacer domain amino acid sequence is selected from GGG (SEQ ID NO: 1), WLMNYFWPL (SEQ ID NO: 42), YLMNYLLPY (SEQ ID NO: 43), PKSALQEL (SEQ ID NO: 44), IGVVISAV (SEQ ID NO: 45), KGSVYLLPY (SEQ ID NO: 46), and WLMNLSAD (SEQ ID NO: 47).
24. The chimeric peptide of claim 1, wherein the inorganic binding domain amino acid sequence is RPRENRGRERGL (SEQ ID NO: 7); the antimicrobial domain acid sequence is LKLLKKLLKLLKKL (SEQ ID NO: 8); and the spacer domain amino acid sequence is selected from: WLMNYFWPL (SEQ ID NO: 42), YLMNYLLPY (SEQ ID NO: 43), PKSALQEL (SEQ ID NO: 44), and KGSVLSAD (SEQ ID NO: 23).
25. The chimeric peptide of claim 1, wherein the inorganic binding domain amino acid sequence is RPREQRGERPRP (SEQ ID NO: 56); the antimicrobial domain acid sequence is LKLLKKLLKLLKKL (SEQ ID NO: 8); and the spacer domain amino acid sequence is selected from: GGG (SEQ ID NO: 1); GSGGG (SEQ ID NO: 2); WLMNYFWPL (SEQ ID NO: 42), YLMNYLLPY (SEQ ID NO: 43), PKSALQEL (SEQ ID NO: 44), and KGSVLSAD (SEQ ID NO: 23).
26. The chimeric peptide of claim 1, wherein the chimeric peptide is (SEQ ID NO: 9)RPRENRGRERGLGGGLKLLKKLLKLLKKL; (SEQ ID NO: 10)RPRENRGRERGLGSGGGLKLLKKLLKLLKKL; (SEQ ID NO: 57)RPRENRGRERGLWLMNYFWPLLKLLKKLLKLLKKL; (SEQ ID NO: 58)RPRENRGRERGLYLMNYLLPYLKLLKKLLKLLKKL; (SEQ ID NO: 59)RPRENRGRERGLPKSALQELLKLLKKLLKLLKKL; (SEQ ID NO: 60)RPRENRGRERGLKGSVLSADLKLLKKLLKLLKK; (SEQ ID NO: 61)RPREQRGERPRPWLMNYFWPLLKLLKKLLKLLKKL; (SEQ ID NO: 62)RPREQRGERPRPYLMNYLLPYLKLLKKLLKLLKKL; (SEQ ID NO: 63)RPREQRGERPRPPKSALQELLKLLKKLLKLLKKL; (SEQ ID NO: 64)RPREQRGERPRPKGSVLSADLKLLKKLLKLLKK; (SEQ ID NO: 65)RPREQRGERPRPGGGLKLLKKLLKLLKKL; (SEQ ID NO: 66)RPREQRGERPRPGSGGGLKLLKKLLKLLKKL; (SEQ ID NO: 24)GRAVRRSIRRRVGSGGGLKLLKKLLKLLKK;(SEQ ID NO: 25)GRAVRRSIRRRVGSGGGKWKLWKKIEKWGQGIGAVLKWLTTWL; (SEQ ID NO: 26)GRAVRRSIRRRVKGSVLSADLKLLKKLLKLLKK; (SEQ ID NO: 27)GRAVRRSIRRRVKGSVLSADKWKLWKKIEKWGQGIGAVLKWLTTWL; (SEQ ID NO: 28)GRAVRRSIRRRVGGGLKLLKKLLKLLKK; (SEQ ID NO: 29)GRAVRRSIRRRVGGGKWKLWKKIEKWGQGIGAVLKWLTTWL; (SEQ ID NO: 30)AIRGIRGIRGIRGSGGGLKLLKKLLKLLKK; (SEQ ID NO: 31)AIRGIRGIRGIRGSGGGKWKLWKKIEKWGQGIGAVLKWLTTWL; (SEQ ID NO: 32)AIRGIRGIRGIRKGSVLSADLKLLKKLLKLLKK; (SEQ ID NO: 33)AIRGIRGIRGIRKGSVLSADKWKLWKKIEKWGQGIGAVLKWLTTWL; (SEQ ID NO: 34)AIRGIRGIRGIRGGGLKLLKKLLKLLKK; (SEQ ID NO: 35)AIRGIRGIRGIRGGGKWKLWKKIEKWGQGIGAVLKWLTTWL; (SEQ ID NO: 38)CMLPHHGACGGGKRWWKWWRR; (SEQ ID NO: 48)RPRENRGRERFIGVVISAVLKLLKKLLKLLKKL; (SEQ ID NO: 49)RPRENRGRERFWLMNYFWPLLKLLKKLLKLLKKL; (SEQ ID NO: 50)RPRENRGRERFYLMNYLLPYLKLLKKLLKLLKKL; (SEQ ID NO: 51)RPRENRGRERFPKSALQELLKLLKKLLKLLKKL; (SEQ ID NO: 52)RPRENRGRERFGGGLKLLKKLLKLLKKL; (SEQ ID NO: 53)RPRENRGRERFKGSVYLLPYLKLLKKLLKLLKK; (SEQ ID NO: 54)RPRENRGRERFWLMNLSADLKLLKKLLKLLKKL;and (SEQ ID NO: 55)RPRENRGRERFKGSVLSADLKLLKKLLKLLKKL.
27. (canceled)
28. (canceled)
29. (canceled)
30. (canceled)
31. (canceled)
32. A coated inorganic substrate comprising a layer of the chimeric peptide of claim 1 on a surface of an inorganic substrate.
33. (canceled)
34. A method of making the coated inorganic substrate of claim 32, comprising contacting the inorganic substrate with a solution of the chimeric peptide.
35. (canceled)
</claims>
</document>
